Skip to content
Life Sciences Series A Founded 2010

Amadix

Provider of diagnostic tools to support personalized cancer treatment. The company has developed prognostic, diagnostic, and predictive tests for lung cancer, colorectal cancer, and prostate cancer. Its colon cancer test ColoFast is a blood-based miRNA test for early detection of colon cancer. It is also developing DiagnoLung which is a blood-based ELISA test that measures the level of three protein biomarkers to…

📍 Madrid, Spain · Genomics,

Funding snapshot

Last roundSeries A
Amount$16M
Date14 February 2025
Total raised$7M
Team size46

About

Provider of diagnostic tools to support personalized cancer treatment. The company has developed prognostic, diagnostic, and predictive tests for lung cancer, colorectal cancer, and prostate cancer. Its colon cancer test ColoFast is a blood-based miRNA test for early detection of colon cancer. It is also developing DiagnoLung which is a blood-based ELISA test that measures the level of three protein biomarkers to screen high-risk patients for non-small-cell lung cancer. The company operates in the Genomics sector with additional focus on Oncology and Clinical Genomics. Its business model centers on Lung cancer. Founded in 2010, headquartered in Madrid, Spain. The company has raised $6.9M at the Series A stage. Backed by investors including Europa, CRB Inverbio, Inveready, Alentia, EIC Fund and others.

Business model

Oncology > In-Vitro Diagnostic Tests > Lung cancer,

Genomics > Applied Genomics > Clinical Genomics > Diagnostics > Sequencing-based > Liquid Biopsy > DNA and RNA

Institutional investors

Europa CRB Inverbio Inveready Alentia EIC Fund European Investment Bank Clave GENESIS Biomed Desafia EIT Health

Latest coverage

No articles yet.

Raising like Amadix?

Analyze your pitch deck before your next raise.

Analyze My Deck →